What to know about new research indicating lithium can help protect against Alzheimer's disease
The researchers also fed healthy mice a lithium-restricted diet, spurring memory problems: they had trouble performing several laboratory memory tests. And finally, the researchers were also able to reverse disease-related damage and restore memory function, even in older mice with advanced disease, by returning lithium to their diet.
Advertisement
What kind of lithium was used in the study?
The researchers used a different form of lithium than is typically used to treat psychiatric disorders, such as bipolar disorder. They used
Advertisement
Should you buy lithium online or in stores and start taking it?
Lithium, like other supplements or vitamins sold online or in stores, is
How else should I get lithium in my diet?
Many foods already touted for their health benefits naturally contain higher amounts of lithium —
What else can I do to lower my risk of Alzheimer's disease?
Another
Scientists say the new lithium findings are exciting, but urge people not to rush out and buy supplements before researchers can test lithium orotate in a large clinical trial with one group of participants receiving small doses of lithium orotate and the others a sham substance, to compare the findings. The trials would need to identify the dosage and duration of time for taking the substance.
Advertisement
Kay Lazar can be reached at
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
NHC Reports Second Quarter 2025 Earnings
MURFREESBORO, Tenn.--(BUSINESS WIRE)-- National HealthCare Corporation (NYSE American: NHC), the nation's oldest publicly traded senior health care company, announced today net operating revenues for the quarter ended June 30, 2025 totaled $374,910,000 compared to $300,658,000 for the quarter ended June 30, 2024, an increase of 24.7%. The increase in net operating revenues for the second quarter of 2025 compared to the second quarter of 2024 was due to an 9.6% increase in same-facility net operating revenues, as well as the August 1, 2024 acquisition of White Oak Management, Inc. ('White Oak'). For the quarter ended June 30, 2025, the reported GAAP net income attributable to NHC was $23,722,000 compared to $26,844,000 for the same period in 2024. Excluding the unrealized gains and losses in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income for the quarter ended June 30, 2025 was $25,710,000 compared to $15,612,000 for the same period in 2024, an increase of 64.7% (*). The GAAP diluted earnings per share were $1.52 and $1.73 for the quarters ending June 30, 2025 and 2024, respectively. Adjusted diluted earnings per share were $1.65 and $1.00 for the quarters ending June 30, 2025 and 2024, respectively (*). (*) - See the tables below that provide a reconciliation of GAAP to non-GAAP items. Expand About NHC As of August 1, 2025, NHC affiliates operate for themselves and third parties 80 skilled nursing facilities with 10,329 beds. NHC affiliates also operate 26 assisted living communities with 1,413 units, nine independent living communities with 777 units, three behavioral health hospitals, 34 homecare agencies, and 33 hospice agencies. NHC's other services include Alzheimer's and memory care units, pharmacy services, a rehabilitation services company, and providing management and accounting services to third party post-acute operators. Other information about the company can be found on our web site at Non-GAAP Financial Presentation The Company is providing certain non-GAAP financial measures as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods. Therefore, the Company believes this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The presentation of this additional non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Forward-Looking Statements Statements in this press release that are not historical facts are forward-looking statements. NHC cautions investors that any forward-looking statements made involve risks and uncertainties and are not guarantees of future performance. The risks and uncertainties are detailed from time to time in reports filed by NHC with the S.E.C., including Forms 8-K, 10-Q, and 10-K. All forward-looking statements represent NHC's best judgment as of the date of this release. Selected Operating Statistics Three Months Ended Six Months Ended June 30 June 30 2025 2024 2025 2024 (unaudited) (unaudited) Skilled Nursing Per Diems: Medicare $ 614.85 $ 577.71 $ 613.47 $ 579.81 Managed Care 486.17 447.96 489.30 459.48 Medicaid 286.43 264.49 284.07 264.88 Private Pay and Other 341.34 312.91 339.24 310.31 Average Skilled Nursing Per Diem $ 361.42 $ 338.86 $ 360.78 (1) $ 341.21 (1) Skilled Nursing Patient Days: Medicare 83,615 74,602 169,869 155,758 Managed Care 83,015 62,957 166,661 128,388 Medicaid 368,687 279,504 732,329 561,325 Private Pay and Other 194,202 150,234 378,796 307,677 Total Skilled Nursing Patient Days 729,519 567,297 1,447,655 (1) 1,153,148 (1) (1) NHC exited three skilled nursing facilities in Missouri on March 1, 2024. For the six months ended June 30, 2024, the exited Missouri skilled nursing facilities had an average skilled nursing per diem of $275.64 and 20,267 patient days. The tables below provide reconciliations of GAAP to non-GAAP items (in thousands, except per share amounts): Three Months Ended Six Months Ended June 30 June 30 2025 2024 2025 2024 (unaudited) (unaudited) Net income attributable to National Healthcare Corporation $ 23,722 $ 26,844 $ 55,927 $ 53,057 Non-GAAP adjustments Unrealized (gains)/losses on marketable equity securities 5,061 (9,124 ) (5,921 ) (23,523 ) Operating losses for newly-opened operations not at full capacity - 20 - 20 Gain on sale of property and equipment (3,606 ) - (3,606 ) - Gain on sale of unconsolidated company - - - (1,024 ) Stock-based compensation expense 1,232 1,176 2,260 1,969 Acquisition-related expenses - 2,194 - 2,194 Employee retention credit - (9,445 ) - (9,445 ) Income tax provision/(benefit) on non-GAAP adjustments (699 ) 3,947 1,889 7,750 Non-GAAP Net income $ 25,710 $ 15,612 $ 50,549 $ 30,998 GAAP diluted earnings per share $ 1.52 $ 1.73 $ 3.59 $ 3.42 Non-GAAP adjustments Unrealized (gains)/losses on marketable equity securities 0.32 (0.59 ) (0.38 ) (1.51 ) Gain on sale of property and equipment (0.23 ) - (0.23 ) - Gain on sale of unconsolidated company - - - (0.07 ) Stock-based compensation expense 0.08 0.08 0.14 0.13 Acquisition-related expenses - 0.14 - 0.14 Employee retention credit - (0.61 ) - (0.61 ) Income tax provision/(benefit) on non-GAAP adjustments (0.04 ) 0.25 0.12 0.50 Non-GAAP diluted earnings per share $ 1.65 $ 1.00 $ 3.24 $ 2.00 Expand
Business Wire
18 hours ago
- Business Wire
C2N Announces Major Global Expansion, Adds Six New International Partners
ST. LOUIS--(BUSINESS WIRE)-- C2N Diagnostics, LLC ('C2N'), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is reaching additional global healthcare providers eager to use its PrecivityAD2™ blood test to help diagnose Alzheimer's disease. The PrecivityAD2™ blood test allows healthcare providers to determine the presence or absence of amyloid pathology, a known hallmark of Alzheimer's disease, for patients being evaluated for cognitive complaints through a simple, non-invasive blood test. Dr. Joel Braunstein, CEO of C2N Diagnostics, says, 'These new international partnerships are intended to broaden access to C2N's innovative Precivity™ portfolio of blood tests in markets facing growing healthcare pressures given aging populations." Share The company has secured partnerships with six new clinical reference laboratories and distributors, expanding its footprint to over seven additional countries. C2N's new partnerships are with: C2N also maintains partnerships with leading labs around the world, including Grupo Fleury, Healius, Mayo Clinic Laboratories, and Unilabs, along with a research collaboration with Mediford. Dr. Joel Braunstein, CEO of C2N Diagnostics, says, 'These new international partnerships are intended to broaden access to C2N's innovative Precivity™ portfolio of blood tests in markets facing growing healthcare pressures given aging populations, a lack of dementia specialists, and inadequate PET infrastructure. These partnerships are a testament to the science and research that have already assisted healthcare providers in delivering a clear picture of Alzheimer's disease pathology to patients and their families in many countries. The growing burden of Alzheimer's disease requires the healthcare system to explore new ways to offer less costly and more accessible diagnostic testing, and we look forward to helping more patients around the world receive an early and accurate diagnosis.' The PrecivityAD2™ blood test involves a simple blood draw from the patient and is intended for patients aged 55 and older with signs or symptoms of cognitive impairment who are undergoing evaluation for Alzheimer's disease or other causes of cognitive decline. PrecivityAD2™ Blood Test is Rigorously Analytically and Clinically Validated; Has High Accuracy The Journal of the American Medical Association (JAMA) published a large clinical care study examining the ability of the PrecivityAD2 blood test algorithm to improve the diagnostic accuracy of Alzheimer's disease in primary care settings, where most patients with cognitive concerns turn to for initial answers about their memory loss. The study found the PrecivityAD2™ test result delivered a highly statistically significant accuracy of over 90% at a pre-defined, single binary cutoff compared to cerebrospinal fluid (CSF) analysis or amyloid PET analysis. All C2N's Precivity™ tests are currently performed under the ISO 13485:2016 standard and in the company's CAP accredited, CLIA certified laboratory. About C2N Diagnostics, LLC C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N's high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 150 Alzheimer's disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer's disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer's Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, Mayo Clinic Laboratories, and Unilabs. Over 50,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review. The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer's Drug Discovery Foundation, BrightFocus Foundation, and Alzheimer's Association. For more information visit
Vox
19 hours ago
- Vox
Headphones that scan your brainwaves and keep you focused? It's not science fiction.
is a senior technology correspondent at Vox and author of the User Friendly newsletter. He's spent 15 years covering the intersection of technology, culture, and politics at places like The Atlantic, Gizmodo, and Vice. The MW75 Neuro headphones are primarily used to sharpen your attention — with the new and added benefit of giving you a snapshot of your brain health. Paige Vickers/Vox; Getty Images; Neurable For the past few months, when I really needed to get something done, I put on a special pair of headphones that could read my mind. Well, kind of. The headphones are equipped with a brain-computer interface that picks up electrical signals from my brain and uses algorithms to interpret that data. When my focus starts to slip, the headphones know it, and an app tells me to take a break. It sounds like something out of science fiction, but a decade-old startup called Neurable is pioneering the technology, and it's preparing to put the brain-tracking tricks into more gadgets. Earbuds, glasses, helmets — anything that can get an electrode near your head could provide a real-time stream of data about what's going on inside of it. Neurable's technology uses a combination of electroencephalography (EEG) sensors to collect brain data and algorithms to interpret those signals. Beyond measuring attention, the company is now using that data to track and improve brain health. User Friendly A weekly dispatch to make sure tech is working for you, instead of overwhelming you. From senior technology correspondent Adam Clark Estes. Email (required) Sign Up By submitting your email, you agree to our Terms and Privacy Notice . This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. I want to emphasize again that this technology does not actually read your mind in the sense of knowing your thoughts. But, it knows when you're entertained or distracted and could one day detect symptoms of depression or, on a much more consequential front, early signs of Alzheimer's disease. I came across Neurable on a longer mission to understand the future of health-tracking technology by testing what's out there now. It's one that left me anxious, covered in smart rings and continuous glucose monitors, and more confused about the definition of well-being. That's because almost all health trackers that are popular on the market right now — Apple Watches, Oura Rings, Whoop Bands — are downstream sensors. They measure consequences, like elevated heart rate or body temperature, rather than the root cause of that state. By tapping directly into your brainwaves, a brain-computer interface can spot issues sometimes years before they would show up. It could one day detect symptoms of depression or, on a much more consequential front, early signs of Alzheimer's disease. 'Biologically, your brain is designed to hide your weaknesses: It's an evolutionary effect,' Neurable's co-founder and CEO Ramses Alcaide, a neuroscientist, told me. 'But when you're measuring from the source, you pick up those things as they're occurring, instead of once there's finally downstream consequences, and that's the real advantage of measuring the brain.' Other major tech companies are also exploring ways to incorporate non-invasive brain-computer interfaces into headphones. A couple years ago, Apple quietly applied for a patent for an AirPod design that uses electrodes to monitor brain activity, and NextSense, which grew out of Google's moonshot division, wants to build earbud-based brain monitors for the mass market. There's also been a recent boom in activity around invasive brain-computer interfaces being developed by companies like Elon Musk's Neuralink and even Meta that surgically implant chips into people's brains. It's safe to say that's not currently a mass-market approach. Still, while all of those mega market cap companies ponder the possibilities of their own brain-powered projects, Neurable's is on the market. It's on my head right now, actually, and it works. The cutting edge of neurotech The Master & Dynamic MW75 Neuro — the $700 pair of headphones I tested — looks like any other set of noise-canceling headphones, except for the badge that reads, 'Powered by Neurable AI.' When you connect them to the Neurable app is when things get fun. Inside the Neurable app is a little video game that lets you fly a rocket ship with your brain — and serves as a proof of concept. The trick is you have to focus on a set of numbers on the screen. The more intensely you focus, the higher the numbers go, and the faster the rocket ship flies. If you start to get distracted by, say, thinking about flying an actual rocket ship, the numbers go down, and the rocket ship slows. It's one of the coolest innovations I've ever seen, if only because it's so simple. The EEG sensors in Neurable's products can pick up a range of brainwave frequencies, which are associated with different behaviors and activities. The beta frequency band provides some information about attention state as well as anxiety, while alpha indicates a mind at rest. While EEG sensors and brain-computer interfaces are most often seen in labs, putting these sensors into a device that people wear every day stands to transform our understanding of the mind. 'Non-invasive EEG is cheap and completely safe,' said Bin He, a professor of biomedical engineering at Carnegie Mellon University, whose lab built a drone you can fly with your mind over a decade ago. 'AI, or deep-learning technology, however has drastically improved the performance of [brain-computer interfaces] to read the minds of individuals.' If you changed the technology's mission from measuring focus to, say, symptoms of depression, you could imagine how an everyday gadget could offer some life-changing interventions. The possibilities are as endless as the list of issues that can affect the brain. The Pentagon has been using Neurable's portable technology to study traumatic head injuries in soldiers, for instance, and that research could have practical applications in sports. Alcaide also mentioned Alzheimer's and Parkinson's as potential targets for their technology. Symptoms for these diseases don't appear for years after onset, but early markers could show up in the kind of EEG data their technology captures from everyday wear. If you changed the technology's mission from measuring focus to, say, symptoms of depression, you could imagine how an everyday gadget could offer some life-changing interventions. For now, however, the MW75 Neuro headphones are primarily used to sharpen your attention — with the new and added benefit of giving you a snapshot of your brain health. This involves starting a session with the headphones on and letting the sensors collect the electrical signals your brain's sending off. Your focus is measured as low, medium, or high, and when you're flagging for a while, the app will prompt you to take a break. You can also turn on a feature called Biofeedback, which plays music of varying intensity in order to nudge your focus toward the high range. The Brain Health reports are still in beta mode but will show you daily estimates of how you're doing in terms of things like anxiety resistance, cognitive speed, and wakefulness. The way you know that the device isn't actually reading your mind comes down to science and a strong data policy. Neurable's technology picks up raw voltage — not actual thoughts — from your neurons and uses AI to decode the data and identify signals associated with focus, the company's co-founder Adam Molnar explained to me recently. Neurable encrypts and anonymizes the data coming out of your head and onto its sensors and then again when it goes to your phone, so it's far removed from any personal data. Furthermore, he said, Neurable has no ambitions to be a data company. 'Our business model doesn't depend on identity. We don't sell ads. So there's no benefit,' Molnar said. 'It's actually more of a liability for us to be able to have data map back to an individual.' It's hard for me to say how much more productive I became thanks to the brain-reading headphones. As with many other health trackers, there's sort of a placebo cat effect: Simply deciding to track the behavior changed my state of mind and made me behave a certain way. So, setting up a focus session inevitably made me pay closer attention to how well I was focusing, how often I took breaks, and if I was choosing to be more mindful. This is actually what makes me so curious about an earbud version of what Neurable's doing. I wear AirPods for most of the day, whether it's taking calls for work, listening to podcasts, or just drowning out the sounds outside my Brooklyn apartment. If these earbuds were also collecting data about my cognitive well-being during all those activities, I'd be interested in knowing what I could glean from that information, if only to better understand what's rotting my brain. And I'm sure plenty of companies would be happy to collect more data about their users' states of mind at any given time. Imagine if the TikTok algorithm knew you weren't interested in something — not because you swiped through it but rather because your brainwaves said so. Neurable's website has mockups of EEG-equipped earbuds, helmets, and smart glasses, and it's clear that the company is eager to move beyond its first product. The company doesn't just want to make gadgets, either. It wants to be the leading platform for brain-powered technology. 'Just like Bluetooth is in every single device, and everyone should have access to Bluetooth, we believe that everyone should have access to neuro tech,' Alcaide told me. We're years away from the most far-fetched applications of brain-computer interfaces, but we're heading in that direction. 'There's so many things you can do with neuro tech, whether it's tracking health conditions, whether it's controlling devices, whether it is understanding yourself better,' he said. 'It would be a disservice to the world if the only solutions that came out were our own.' Neurable is indeed one of many startups trying to bring neuro tech to the masses, although they're the only ones selling a product I'd actually wear in public. Several other EEG-based gadgets out there take the form of headbands, many of which are geared toward sleep health or meditation. A company called Emotiv, which also partnered with Master & Dynamic, will start selling its own EEG-equipped earbuds this fall. It remains to be seen if and when Apple will make brain-reading AirPods, but they've already partnered with a brain interface startup called Synchron, which allows people to control iPhones with their minds (Haven't you always wanted to become one with your iPhone?). This is where we circle back to the point where science fiction meets reality. We're years away from the most far-fetched applications of brain-computer interfaces, but we're heading in that direction. Whether that future ends up looking miraculous or like a Black Mirror episode is up to us — and to the companies, like Neurable, pioneering it.
